HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Yoshiki Sawa Yoshiaki Takewa Hikaru Matsuda Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shirakawa, Y. Articles by Matsuda, H. Search for Related Content PubMed PubMed Citation Articles by Shirakawa, Y. Articles by Matsuda, H. Related Collections Congestive Heart Failure Mechanical Circulatory Assistance

J Thorac Cardiovasc Surg 2005;130:624-632
© 2005 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Gene transfection with human hepatocyte growth factor complementary DNA plasmids attenuates cardiac remodeling after acute myocardial infarction in goat hearts implanted with ventricular assist devices

^a Department of Surgery, E1, Division of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
^b Department of Artificial Organs, National Cardiovascular Center Research Institute, Osaka, Japan
^c Department of Gene Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan

Received for publication October 16, 2003; revisions received February 15, 2004; accepted for publication February 26, 2004.

^_* Address for reprints: Hikaru Matsuda, MD, PhD, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan (Email: matsuda{at}surg1.med.osaka-u.ac.jp).

BACKGROUND: Although a left ventricular assist device is often used to provide circulatory support until transplantation in severe heart failure, the mortality of long-term use of left ventricular assist devices remains high. We have shown that hepatocyte growth factor causes angiogenesis, antifibrosis, and antiapoptosis in the myocardium. Therefore, gene therapy with hepatocyte growth factor–complementary DNA plasmids may enhance the chance of "bridge to recovery." In this study, we performed gene therapy with hepatocyte growth factor in the impaired goat heart with a left ventricular assist device.

METHODS: Cardiac impairment was induced in 6 adult goats (56-65 kg) by ligation of the coronary artery, and ventricular assist devices were installed. The hepatocyte growth factor group (HGF; n = 3) was administered human hepatocyte growth factor–complementary DNA plasmid (2.0 mg) in the myocardium. The control group (n = 3) was similarly administered ß-galactosidase plasmid. Four weeks after gene transfection, we attempted to wean all goats from the ventricular assist device.

RESULTS: The myocardia transfected with human hepatocyte growth factor–complementary DNA contained human hepatocyte growth factor protein at levels as high as 1.0 ± 0.3 ng/g tissue 3 days after transfection. After weaning from the ventricular assist device, the HGF group showed good hemodynamics, whereas the control group showed deterioration. The percentage of fractional shortening was significantly higher in the HGF group than the control group (HGF vs control, 37.9% ± 1.7% vs 26.4% ± 0.3%, respectively; P < .01). Left ventricular dilatation associated with myocyte hypertrophy and fibrotic changes was detected in the control group but not in the HGF group. Vascular density was markedly increased in the HGF group.

CONCLUSIONS: These results suggest that gene therapy with human hepatocyte growth factor may enhance the chance of bridge to recovery in the impaired heart supported with a ventricular assist device.

This article has been cited by other articles:

				M. Carlsson, N. F. Osman, P. C. Ursell, A. J. Martin, and M. Saeed Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H522 - H532. [Abstract] [Full Text] [PDF]